Edap TMS SA (EDAP)
2.69
-0.17
(-5.94%)
USD |
NASDAQ |
Nov 04, 16:00
2.72
+0.03
(+1.12%)
After-Hours: 20:00
Edap TMS Research and Development Expense (Annual): 7.538M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.538M |
| December 31, 2022 | 5.189M |
| December 31, 2021 | 4.025M |
| December 31, 2020 | 5.135M |
| December 31, 2019 | 4.174M |
| December 31, 2018 | 4.827M |
| December 31, 2017 | 4.395M |
| December 31, 2016 | 4.281M |
| December 31, 2015 | 2.985M |
| December 31, 2014 | 3.899M |
| December 31, 2013 | 3.446M |
| December 31, 2012 | 3.418M |
| December 31, 2011 | 3.397M |
| December 31, 2010 | 4.332M |
| Date | Value |
|---|---|
| December 31, 2009 | 5.091M |
| December 31, 2008 | 5.448M |
| December 31, 2007 | 4.379M |
| December 31, 2006 | 3.069M |
| December 31, 2005 | 2.218M |
| December 31, 2004 | 1.893M |
| December 31, 2003 | 3.468M |
| December 31, 2002 | 3.016M |
| December 31, 2001 | 3.078M |
| December 31, 2000 | 3.679M |
| December 31, 1999 | 3.346M |
| December 31, 1998 | 3.631M |
| December 31, 1997 | 3.807M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.025M
Minimum
2021
7.538M
Maximum
2023
5.212M
Average
5.135M
Median
2020
Research and Development Expense (Annual) Benchmarks
| DBV Technologies SA | 60.22M |
| Genfit SA | 50.57M |
| Cellectis SA | 87.65M |
| Adaptimmune Therapeutics PLC | 126.51M |
| Akari Therapeutics PLC | 5.45M |